Recent Company News

• 10:37 AM ET Apr 24, 2026
  

  Transcript Intelligence: Xvivo Perfusion Q1 Earnings Guidance

• 10:37 AM ET Apr 24, 2026
  

  Transcript Intelligence: Xvivo Perfusion Q1 Earnings Themes

• 10:37 AM ET Apr 24, 2026
  

  Transcript Intelligence: Xvivo Perfusion Q1 Earnings Q&A

• 01:37 AM ET Apr 24, 2026
  

  Xvivo Perfusion reports Q1 EPS SEK1.15 vs FactSet SEK0.94 [4 est, SEK0.76-1.34]

• 04:15 PM ET Apr 22, 2026
  

  Xvivo Perfusion presents results from HOPE-at-Heart clinical trial using hypothermic oxygenated perfusion (Hope) in direct procurement DCD heart transplantation (SEK 295.60, 0.00)

• 03:02 PM ET Apr 22, 2026
  

  Xvivo Perfusion announces data from PRESERVE Trial (SEK 295.60, 0.00)

• 08:02 AM ET Apr 16, 2026
  

  The 12-month follow-up results from XVIVO's European multicenter heart trial is now published in the European Heart Journal (SEK 297.40, +8.20)

• 04:10 AM ET Apr 01, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 06:27 AM ET Mar 17, 2026
  

  Transcript Intelligence: Xvivo Perfusion at Oppenheimer Healthcare MedTech & Services Conference

• 10:47 AM ET Feb 19, 2026
  

  Xvivo Perfusion announces CFO Kristoffer Nordström to transfer to new role; recruitment process for successor initiated (SEK 184.80, +4.30)